轩竹生物-B(02575)：安奈拉唑钠新适应症根除幽门螺杆菌之III期临床试验完成首例患者入组

智通财经06-21

智通财经APP讯，轩竹生物-B(02575)发布公告，团自主研发的创新药安奈拉唑钠肠溶片(商品名：安久卫®)用于含安奈拉唑钠的铋剂四联疗法根除幽门螺杆菌(“Hp”)之III期临床研究，近日已成功完成首例患者入组，标志着该项关键注册临床研究正式迈入实质性执行阶段。该研究是一项多中心、随机、双盲双模拟、阳性药平行对照的III期临床试验，计划纳入556例幽门螺杆菌阳性成人受试者，以含艾司奥美拉唑镁的铋剂...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2645097981?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-21 18:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645097981","market":"sh","top_or_hot":-1,"title":"轩竹生物-B(02575)：安奈拉唑钠新适应症根除幽门螺杆菌之III期临床试验完成首例患者入组","media":"智通财经","content":"<div>\n<p>智通财经APP讯，轩竹生物-B(02575)发布公告，团自主研发的创新药安奈拉唑钠肠溶片(商品名：安久卫®)用于含安奈拉唑钠的铋剂四联疗法根除幽门螺杆菌(“Hp”)之III期临床研究，近日已成功完成首例患者入组，标志着该项关键注册临床研究正式迈入实质性执行阶段。该研究是一项多中心、随机、双盲双模拟、阳性药平行对照的III期临床试验，计划纳入556例幽门螺杆菌阳性成人受试者，以含艾司奥美拉唑镁的铋剂...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1456624.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>轩竹生物-B(02575)：安奈拉唑钠新适应症根除幽门螺杆菌之III期临床试验完成首例患者入组</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n轩竹生物-B(02575)：安奈拉唑钠新适应症根除幽门螺杆菌之III期临床试验完成首例患者入组\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-21 18:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1456624.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，轩竹生物-B(02575)发布公告，团自主研发的创新药安奈拉唑钠肠溶片(商品名：安久卫®)用于含安奈拉唑钠的铋剂四联疗法根除幽门螺杆菌(“Hp”)之III期临床研究，近日已成功完成首例患者入组，标志着该项关键注册临床研究正式迈入实质性执行阶段。该研究是一项多中心、随机、双盲双模拟、阳性药平行对照的III期临床试验，计划纳入556例幽门螺杆菌阳性成人受试者，以含艾司奥美拉唑镁的铋剂...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1456624.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4134","symbol_name":"信息科技咨询与其它服务","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1456624.html","article_id":"2645097981","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645097981","pubTimestamp":1782036715,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，轩竹生物-B 发布公告，团自主研发的创新药安奈拉唑钠肠溶片用于含安奈拉唑钠的铋剂四联疗法根除幽门螺杆菌之III期临床研究，近日已成功完成首例患者入组，标志着该项关键注册临床研究正式迈入实质性执行阶段。本次Hp根除适应症III期临床研究于2026年4月获中国国家药品监督管理局药品审评中心批准开展后，迅速完成首例患者入组，充分彰显公司临床开发团队的高效执行能力，亦标志该项目正式进入临床执行关键阶段。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4134":"信息科技咨询与其它服务","02575":"轩竹生物-B","BK1191":"制药","III":"信息服务"},"translate_title":"Xuanzhu Bio-B (02575): Phase III clinical trial of Helicobacter pylori eradication for new indication of aneprazole sodium completed the first patient enrollment","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1.5,"02575":1.5},"content_text":"智通财经APP讯，轩竹生物-B(02575)发布公告，团自主研发的创新药安奈拉唑钠肠溶片(商品名：安久卫®)用于含安奈拉唑钠的铋剂四联疗法根除幽门螺杆菌(“Hp”)之III期临床研究，近日已成功完成首例患者入组，标志着该项关键注册临床研究正式迈入实质性执行阶段。该研究是一项多中心、随机、双盲双模拟、阳性药平行对照的III期临床试验，计划纳入556例幽门螺杆菌阳性成人受试者，以含艾司奥美拉唑镁的铋剂四联疗法为对照，评价含安奈拉唑钠的铋剂四联疗法连续给药14天用于幽门螺杆菌根除治疗的有效性、安全性及群体药代动力学特征，主要终点为治疗结束后第28天经13C-尿素呼气试验(“13C-UBT”)确认的幽门螺杆菌根除率。幽门螺杆菌是一种革兰氏阴性微需氧病原菌，与多种胃部疾病密切相关，包括胃溃疡、慢性进行性胃炎及胃癌。根据弗若斯特沙利文，中国幽门螺杆菌感染率约为44%，治疗幽门螺杆菌感染药物市场规模在持续扩大，2024年中国幽门螺杆菌感染治疗药物市场规模已达人民币55亿元，预测2029年将增至人民币68亿元，到2035年将达到人民币126亿元。本次Hp根除适应症III期临床研究于2026年4月获中国国家药品监督管理局(“NMPA”)药品审评中心(“CDE”)批准开展后，迅速完成首例患者入组，充分彰显公司临床开发团队的高效执行能力，亦标志该项目正式进入临床执行关键阶段。未来该适应症若顺利获批上市，预期将进一步扩大安奈拉唑钠的目标患者群体，加速产品市场放量，为公司打造消化领域新的业绩增长支点。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645097981","isCrawlerRequest":true}